CloudMD Sees Increasing Demand For Telemedicine Offering
CloudMD Software & Services (CSE: DOC) announced this morning that its telemedicine platform has seen excellent growth as of late, with its offering now having over 100,000 registered users. The users are split between its flagship CloudMD app as well as its MyHealthAccess telemedicine offerings.
In terms of the CloudMD app, the program is nearing 10,000 downloads since its launch in late February 2020. The last two weeks haveseen considerable growth, with the application conducting over 1,000 virtual visits within the last two weeks. The growth is over 3x that of the previous comparable period.
Collectively, registrations for CloudMD’s two telemedicine offerings are up over 133% in the last week. The increase is largely a result of users requiring doctor appointments while staying in isolation as a result of the ongoing coronavirus pandemic. The company’s telemed offerings enable patients to conduct these visits remotely, enabling the patient to limit their exposure to others.
CloudMD continues to revolutionize the way healthcare is delivered to patients. We are excited and encouraged by the continued growth of our CloudMD platform as the significant increase in registered users continues to reinforce buy-in from the communities we serve. During these difficult times we are proud to offer much needed and timely medical care to the Canadian population. We remain committed to providing the best health care services to our patients.
Dr. Essam Hamza, CEO of CloudMD
CloudMD Software & Services last traded at $0.43 on the CSE.
FULL DISCLOSURE: CloudMD Software & Services is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover CloudMD Software & Services on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
